EUVIMEDEUVIMED entdecken
Crossref

Intolerance of oral methotrexate in juvenile idiopathic arthritis

Ai Yuda, Tomo Nozawa, Seira Hattori, Ayako Murase, Kenichi Nishimura, Ryoki Hara, Shuichi Ito iD

Pediatrics International · 2025-01 · 67 (1)

DOI: 10.1111/ped.70112 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatrics International, online erschienen am 20.06.2025. Verfasst von Ai Yuda und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan. Hauptthemen laut MEDLINE: Methotrexate, Arthritis, Juvenile, Antirheumatic Agents, Vomiting. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Oral methotrexate (MTX) is a cornerstone treatment for juvenile idiopathic arthritis (JIA), although adverse events (AEs) such as nausea and vomiting often impact adherence. This study examined the intolerability of MTX in patients with JIA.

Methods

We retrospectively investigated MTX intolerability in 52 patients treated at our institute between April 2011 and October 2022. The target MTX dose was 10 mg/m 2 /week (maximum 16 mg/week) according to the Japanese clinical guidelines for JIA.

Results

The median age at MTX initiation was 8.3 years, with a median maximum dose of 8.9 mg/m 2 /week. Of the 52 patients, 16 (31%) were started on biologics before or at the initiation of MTX, while 36 (69%) began MTX monotherapy. Fifteen (29%) patients could not reach the target MTX dose because of AEs. Thirty‐six (68%) patients experienced one or more AEs, with nausea and vomiting being the most common ( n = 24). Eleven patients (21%) failed to achieve or maintain remission because of intractable nausea/vomiting, and nine (17%) eventually required biologics. Among the 24 patients who experienced nausea/vomiting, 42% developed symptoms within 6 months and 67% within 12 months of MTX initiation. AEs occurred regardless of MTX dose.

Conclusions

Two‐thirds of patients experienced AEs with oral MTX, leading some to fail remission and require biologics. Intolerability of oral MTX was common and significantly influenced patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethotrexateArthritis, JuvenileAntirheumatic AgentsVomitingNauseaHumansRetrospective StudiesFemaleChildMaleAdministration, OralChild, PreschoolAdolescent

Stichwörter der Autor:innen

adverse effectsjuvenile idiopathic arthritismethotrexatenausea/vomitingsubcutaneous

Substanzen

MethotrexateAntirheumatic Agents

Autor:innen und Institutionen

  • Department of Pediatrics, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan.
  • Department of Pediatrics, Nagasaki University Hospital, Nagasaki, Japan.
  • Department of Pediatrics, National Hospital Organization Yokohama Medical Center, Yokohama, Kanagawa, Japan.

ORCID-Profile: Shuichi Ito

Zitieren

APA

Yuda, A., Nozawa, T., Hattori, S., Murase, A., Nishimura, K., Hara, R., & Ito, S. (2025). Intolerance of oral methotrexate in juvenile idiopathic arthritis. Pediatrics International, 67(1). https://doi.org/10.1111/ped.70112

Vancouver

Yuda A, Nozawa T, Hattori S, Murase A, Nishimura K, Hara R, et al. Intolerance of oral methotrexate in juvenile idiopathic arthritis. Pediatrics International. 2025;67(1). doi:10.1111/ped.70112

BibTeX
@article{Yuda2025,
  author = {Yuda, Ai and Nozawa, Tomo and Hattori, Seira and Murase, Ayako and Nishimura, Kenichi and Hara, Ryoki and Ito, Shuichi},
  title = {Intolerance of oral methotrexate in juvenile idiopathic arthritis},
  journal = {Pediatrics International},
  year = {2025},
  volume = {67},
  number = {1},
  doi = {10.1111/ped.70112}
}
Kostenlos starten →